Schizophrenia – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Schizophrenia – Pipeline Review, H1 2017’, provides an overview of the Schizophrenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Schizophrenia

The report reviews pipeline therapeutics for Schizophrenia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Schizophrenia therapeutics and enlists all their major and minor projects

The report assesses Schizophrenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Schizophrenia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Schizophrenia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acadia Pharmaceuticals Inc

Adamed Sp z oo

Aequus Pharmaceuticals Inc

AgeneBio Inc

Alkermes Plc

Angita BV

Astellas Pharma Inc

Athersys Inc

Avanir Pharmaceuticals Inc

Avineuro Pharmaceuticals Inc

BCWorld Pharm Co Ltd

BioCrea GmbH

BioHealthonomics Inc

Boehringer Ingelheim GmbH

Braeburn Pharmaceuticals Inc

Bristol-Myers Squibb Company

Critical Pharmaceuticals Ltd

Curemark LLC

Daewoong Pharmaceutical Co Ltd

Delpor Inc

Denovo Biopharma LLC

Evotec AG

F. Hoffmann-La Roche Ltd

Fabre-Kramer Pharmaceuticals Inc

Galenea Corp

GeNeuro SA

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

GP Pharm SA

GW Pharmaceuticals Plc

H. Lundbeck A/S

Heptares Therapeutics Ltd

Hisamitsu Pharmaceutical Co Inc

Indivior Plc

Insys Therapeutics Inc

IntelGenx Corp

Intra-Cellular Therapies Inc

Johnson & Johnson

JT Pharmaceuticals Inc

Karuna Pharmaceuticals Inc

KemPharm Inc

Kowa Company Ltd

Laboratorios Farmaceuticos Rovi SA

Lead Discovery Center GmbH

Lohocla Research Corp

Luye Pharma Group Ltd

Mapi Pharma Ltd

Merck & Co Inc

Mitsubishi Tanabe Pharma Corp

Neurocrine Biosciences Inc

NeurOp Inc

Newron Pharmaceuticals SpA

Omeros Corp

Otsuka Holdings Co Ltd

Peptron Inc

Pfizer Inc

Promentis Pharmaceuticals Inc

Ra Pharmaceuticals Inc

Reviva Pharmaceuticals Inc

Richter Gedeon Nyrt

Sage Therapeutics Inc

SK Biopharmaceuticals Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Sunovion Pharmaceuticals Inc

Suven Life Sciences Ltd

Taisho Pharmaceutical Holdings Co Ltd

Tetra Discovery Partners LLC

Teva Pharmaceutical Industries Ltd

Vanda Pharmaceuticals Inc

Vitality Biopharma Inc

VLP Therapeutics LLC

Zogenix Inc

Zysis Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Schizophrenia - Overview 7

Schizophrenia - Therapeutics Development 8

Schizophrenia - Therapeutics Assessment 24

Schizophrenia - Companies Involved in Therapeutics Development 36

Schizophrenia - Drug Profiles 73

Schizophrenia - Dormant Projects 274

Schizophrenia - Discontinued Products 282

Schizophrenia - Product Development Milestones 285

Appendix 295

List of Tables

List of Tables

Number of Products under Development for Schizophrenia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Schizophrenia – Pipeline by Acadia Pharmaceuticals Inc, H1 2017

Schizophrenia – Pipeline by Adamed Sp z oo, H1 2017

Schizophrenia – Pipeline by Aequus Pharmaceuticals Inc, H1 2017

Schizophrenia – Pipeline by AgeneBio Inc, H1 2017

Schizophrenia – Pipeline by Alkermes Plc, H1 2017

Schizophrenia – Pipeline by Angita BV, H1 2017

Schizophrenia – Pipeline by Astellas Pharma Inc, H1 2017

Schizophrenia – Pipeline by Athersys Inc, H1 2017

Schizophrenia – Pipeline by Avanir Pharmaceuticals Inc, H1 2017

Schizophrenia – Pipeline by Avineuro Pharmaceuticals Inc, H1 2017

Schizophrenia – Pipeline by BCWorld Pharm Co Ltd, H1 2017

Schizophrenia – Pipeline by BioCrea GmbH, H1 2017

Schizophrenia – Pipeline by BioHealthonomics Inc, H1 2017

Schizophrenia – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Schizophrenia – Pipeline by Braeburn Pharmaceuticals Inc, H1 2017

Schizophrenia – Pipeline by Bristol-Myers Squibb Company, H1 2017

Schizophrenia – Pipeline by Critical Pharmaceuticals Ltd, H1 2017

Schizophrenia – Pipeline by Curemark LLC, H1 2017

Schizophrenia – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Schizophrenia – Pipeline by Delpor Inc, H1 2017

Schizophrenia – Pipeline by Denovo Biopharma LLC, H1 2017

Schizophrenia – Pipeline by Evotec AG, H1 2017

Schizophrenia – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Schizophrenia – Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017

Schizophrenia – Pipeline by Galenea Corp, H1 2017

Schizophrenia – Pipeline by GeNeuro SA, H1 2017

Schizophrenia – Pipeline by GlaxoSmithKline Plc, H1 2017

Schizophrenia – Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Schizophrenia – Pipeline by GP Pharm SA, H1 2017

Schizophrenia – Pipeline by GW Pharmaceuticals Plc, H1 2017

Schizophrenia – Pipeline by H. Lundbeck A/S, H1 2017

Schizophrenia – Pipeline by Heptares Therapeutics Ltd, H1 2017

Schizophrenia – Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2017

Schizophrenia – Pipeline by Indivior Plc, H1 2017

Schizophrenia – Pipeline by Insys Therapeutics Inc, H1 2017

Schizophrenia – Pipeline by IntelGenx Corp, H1 2017

Schizophrenia – Pipeline by Intra-Cellular Therapies Inc, H1 2017

Schizophrenia – Pipeline by Johnson & Johnson, H1 2017

Schizophrenia – Pipeline by JT Pharmaceuticals Inc, H1 2017

Schizophrenia – Pipeline by Karuna Pharmaceuticals Inc, H1 2017

Schizophrenia – Pipeline by KemPharm Inc, H1 2017

Schizophrenia – Pipeline by Kowa Company Ltd, H1 2017

Schizophrenia – Pipeline by Laboratorios Farmaceuticos Rovi SA, H1 2017

Schizophrenia – Pipeline by Lead Discovery Center GmbH, H1 2017

Schizophrenia – Pipeline by Lohocla Research Corp, H1 2017

Schizophrenia – Pipeline by Luye Pharma Group Ltd, H1 2017

Schizophrenia – Pipeline by Mapi Pharma Ltd, H1 2017

Schizophrenia – Pipeline by Merck & Co Inc, H1 2017

Schizophrenia – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Schizophrenia – Pipeline by Neurocrine Biosciences Inc, H1 2017

Schizophrenia – Pipeline by NeurOp Inc, H1 2017

Schizophrenia – Pipeline by Newron Pharmaceuticals SpA, H1 2017

Schizophrenia – Pipeline by Omeros Corp, H1 2017

Schizophrenia – Pipeline by Otsuka Holdings Co Ltd, H1 2017

Schizophrenia – Pipeline by Peptron Inc, H1 2017

Schizophrenia – Pipeline by Pfizer Inc, H1 2017

Schizophrenia – Pipeline by Promentis Pharmaceuticals Inc, H1 2017

Schizophrenia – Pipeline by Ra Pharmaceuticals Inc, H1 2017

Schizophrenia – Pipeline by Reviva Pharmaceuticals Inc, H1 2017

Schizophrenia – Pipeline by Richter Gedeon Nyrt, H1 2017

Schizophrenia – Pipeline by Sage Therapeutics Inc, H1 2017

Schizophrenia – Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017

Schizophrenia – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Schizophrenia – Pipeline by Sunovion Pharmaceuticals Inc, H1 2017

Schizophrenia – Pipeline by Suven Life Sciences Ltd, H1 2017

Schizophrenia – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017

Schizophrenia – Pipeline by Tetra Discovery Partners LLC, H1 2017

Schizophrenia – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Schizophrenia – Pipeline by Vanda Pharmaceuticals Inc, H1 2017

Schizophrenia – Pipeline by Vitality Biopharma Inc, H1 2017

Schizophrenia – Pipeline by VLP Therapeutics LLC, H1 2017

Schizophrenia – Pipeline by Zogenix Inc, H1 2017

Schizophrenia – Pipeline by Zysis Ltd, H1 2017

Schizophrenia – Dormant Projects, H1 2017

Schizophrenia – Dormant Projects, H1 2017 (Contd..1), H1 2017

Schizophrenia – Dormant Projects, H1 2017 (Contd..2), H1 2017

Schizophrenia – Dormant Projects, H1 2017 (Contd..3), H1 2017

Schizophrenia – Dormant Projects, H1 2017 (Contd..4), H1 2017

Schizophrenia – Dormant Projects, H1 2017 (Contd..5), H1 2017

Schizophrenia – Dormant Projects, H1 2017 (Contd..6), H1 2017

Schizophrenia – Dormant Projects, H1 2017 (Contd..7), H1 2017

Schizophrenia – Discontinued Products, H1 2017

Schizophrenia – Discontinued Products, H1 2017 (Contd..1), H1 2017

Schizophrenia – Discontinued Products, H1 2017 (Contd..2), H1 2017

List of Figures

List of Figures

Number of Products under Development for Schizophrenia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports